Pamlico Biopharma

Pamlico develops fully-human monoclonal antibody for the diagnosis and treatment of infectious diseases, such as S. pneumo, hepatitis, TB, influenza, and Ebola.

  • Stage Product In Development
  • Industry Biotechnology
  • Location Oklahoma City, OK, US
  • Currency USD
  • Founded 2012
  • Employees 5
  • Website pamlicobio.com

Company Summary

Pamlico BioPharma develops fully-human monoclonal antibody (hmAb) therapeutics for infectious diseases. Pamlico was founded on technology to rapidly characterize and isolate hmAbs following vaccination. Pamlico isolated antibodies to all 24 serotypes of S. pneumoniae (SPN) and will enter clinical trials in 2016 for a therapeutic and a companion point-of-care (POC) diagnostic against three serotypes that account for over 40% of SPN infections.

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free